C.M. Bidwell & Associates’s Emergent Biosolutions EBS Stock Holding History

C.M. Bidwell & Associates’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,395	Closed	-$247K	–	495
2020 Q3	$247K	Buy	2,395 +530	+28%	+$57.1K	0.23%	78
2020 Q2	$147K	Buy	+1,865	New	+$139K	0.13%	161
2017 Q1	–	Sell	-6,360	Closed	-$209K	–	247
2016 Q4	$209K	Buy	+6,360	New	+$191K	0.05%	155
2014 Q1	–	Sell	-5,530	Closed	-$127K	–	232
2013 Q4	$127K	Hold	5,530	–	–	0.03%	190
2013 Q3	$105K	Hold	5,530	–	–	0.03%	194
2013 Q2	$79.7K	Buy	+5,530	New	+$80.1K	0.02%	206

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

C.M. Bidwell & Associates's EBS Position: Q4 2020 in Review

C.M. Bidwell & Associates sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 2,395 shares — an estimated $247K sold.

C.M. Bidwell & Associates first reported a position in EBS in Q2 2013 and held it in 6 quarters. The position peaked at $247K in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

C.M. Bidwell & Associates reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
C.M. Bidwell & Associates sold 2,395 Emergent Biosolutions shares in Q4 2020, an estimated $247K.
C.M. Bidwell & Associates first reported a position in Emergent Biosolutions in Q2 2013 and held it in 6 quarters.
C.M. Bidwell & Associates's Emergent Biosolutions position peaked at $247K in Q3 2020.
353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2020, filed 16 Feb 2021.